Atormac
Neurology India
Open access journal indexed with Index Medicus
  Users online: 840  
 Home | Login 
  About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe Etcetera Contact  
  Navigate Here 
 Search
 
  » Next article
  » Previous article 
  » Table of Contents
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (344 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  Introduction
 »  Case Reports
 »  Discussion
 »  References

 Article Access Statistics
    Viewed2656    
    Printed108    
    Emailed4    
    PDF Downloaded77    
    Comments [Add]    
    Cited by others 12    

Recommend this journal

 


 
CASE REPORT
Year : 2010  |  Volume : 58  |  Issue : 5  |  Page : 761-763

Gabapentin as a rescue drug in D-penicillamine-induced status dystonicus in patients with Wilson disease


Department of Neurology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Date of Acceptance08-Jul-2010
Date of Web Publication28-Oct-2010

Correspondence Address:
Vimal K Paliwal
Department of Neurology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareily Road, Lucknow - 226 014
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.72184

Rights and Permissions

 » Abstract 

D-penicillamine induced status dystonicus is a unique but serious drug related complication in a subset of patients with Wilson disease. Patho-physiological basis of its occurrence is not known. It often responds poorly to anti dystonia medications. We present three patients with Wilson disease who developed severe paroxysmal dystonic spells after receiving D-penicillamine treatment. All three patients responded well to gabapentin after failing to respond to other anti dystonia drugs.


Keywords: Status dystonicus; D-penicillamine; gabapentin; Wilson′s disease


How to cite this article:
Paliwal VK, Gupta PK, Pradhan S. Gabapentin as a rescue drug in D-penicillamine-induced status dystonicus in patients with Wilson disease. Neurol India 2010;58:761-3

How to cite this URL:
Paliwal VK, Gupta PK, Pradhan S. Gabapentin as a rescue drug in D-penicillamine-induced status dystonicus in patients with Wilson disease. Neurol India [serial online] 2010 [cited 2017 Dec 12];58:761-3. Available from: http://www.neurologyindia.com/text.asp?2010/58/5/761/72184



 » Introduction Top


D-penicillamine is a gold standard treatment for Wilson disease. However, it rarely can cause irreversible aggravation of dystonia in a subset of patients with this disease. Status dystonicus is a life-threatening complication of D-penicillamine therapy in these patients. It responds poorly to anti-dystonia medications.We describe three patients with Wilson disease who developed D-penicillamine-induced status dystonicus for the unique manner of their improvement with gabapentin.


 » Case Reports Top


Case 1

A 15-year-old boy with Wilson disease presented with mouth-open dystonia, fanning of fingers, right hand reaching towards back, extension of great toes, inversion of right foot and flexion of other toes. He received D-penicillamine at a dose of 250 mg daily, which was increased at weekly intervals to 250 mg thrice daily. After a month, he developed sustained pronation, extension of forearms, extension of legs, inversion and planter flexion of feet, facial grimacing and torticollis. A week later, he had episodic spells of intermittent opisthotonic posturing with severe retrocolis, forced extension of extremities and spells of tremor-like movements of limbs lasting 1 to 2 minutes that recurred every 5 to 10 minutes. He remained conscious during the spells. Awake and sleep electroencephalograms (EEG) were normal. D-penicillamine was withdrawn. Despite increasing the dose of diazepam to 30 mg daily, trihexiphenydyl to 24 mg daily and adding tetrabenazine 75 mg daily, the paroxysmal dystonic spells persisted. Intravenous midazolam infusion reduced the dystonic spells transiently. Gabapentin added at 900 mg in three divided doses improved the paroxysmal dystonic spells, which subsided over another week. However, the premorbid sustained dystonia persisted. The patient was given zinc therapy. After one month, gabapentin was withdrawn without reappearance of paroxysmal dystonic spells. No recurrence of dystonic spells was noticed in the last 18 months.

Case 2

A 14-year-old girl with Wilson disease developed severe generalized dystonia after 6 weeks of D-penicillamine (250 mg daily) administration. She developed paroxysmal spells of ophisthotonos; and stiffening of limbs, neck and jaw muscles lasting few minutes. These spells recurred every 2 to 3 minutes. She remained conscious during these spells. In between the subsequent dystonic spells, she had extended legs; inverted, plantar flexed feet; and torticollis. Awake and sleep EEGs were normal. D-penicillamine was discontinued. No response was observed with diazepam (45 mg daily), trihexiphenydyl (30 mg daily) and tetrabenazine (75 mg daily). Gabapentin at 900 mg daily in three divided doses improved the intermittent dystonic spells and produced some improvement in sustained dystonia. Over the next 4 months, no recurrence of dystonic spells was noticed on oral zinc treatment.

Case 3

An 11-year-old boy was diagnosed with Wilson disease 6 months back due to right arm and foot dystonia. He received D-penicillamine at 250 mg thrice daily. After 4 months of D-penicillamine administration, he presented to us for the first time with severe hip flexion, feet almost reaching the head, dorsiflexion at ankle, flexion at toes, abduction flexion of arms, extension with forced supination of both forearms, flexion at wrist, retrocolis and mouth-open dystonia [Video 1].

All these movements increased in paroxysms causing severe pain. Despite discontinuing D-penicillamine for nearly 2 months and being on diazepam (45 mg daily), trihexiphenydyl (45 mg daily) and levodopa (125 mg thrice daily), there was no respite from dystonia. Gabapentin was added at 600 mg in three divided doses. Fourth day onwards, his dystonic spells of sustained hip flexion reduced intermittently for several minutes to about an hour [Video 2].

Before commencement of gabapentin treatment, the child could not bring down his legs on the bed. However, his upper limb and mouth-open dystonia persisted. During the second week after admission, the patient developed septic encephalopathy secondary to a hospital-acquired pneumonia. Despite antibiotics and supportive care, condition of the patient worsened; and on the ninth day after admission, he developed sudden cardiac arrest and died.


 » Discussion Top


D-penicillamine-induced aggravation of dystonia is known in patients with Wilson disease. [1],[2],[3] Similar aggravation of dystonia is also known with Trientine and zinc [4] monotherapies; the condition is however more severe with D-penicillamine. D-penicillamine does not produce dystonia when used in other disorders, like rheumatoid arthritis, copper sulfate or arsenic poisoning. Underlying mechanism of D-penicillamine-induced status dystonicus in Wilson disease is not clear. Increased copper turnover secondary to copper chelation resulting in injury to basal ganglia, thalamus and brainstem is a likely possibility. The signal changes in thalamus and brainstem observed on MRI during D-penicillamine-induced increase in dystonia may reverse back to normal on discontinuation of D-penicillamine. [3]

D-penicillamine-induced status dystonicus responds poorly to anti-dystonia drugs. All our patients responded well to gabapentin after failing to respond to other anti-dystonia drugs. Gabapentin can improve limb dystonia, hemifacial spasms, hemichorea/hemibalismus and torticollis. [5],[6],[7] Interestingly, gabapentin evoked good response in patients with familial paroxysmal nonkinesogenic dyskinesia. [7] In our patients, gabapentin improved paroxysmal dystonic spells more than the sustained dystonia. Mechanism of gabapentin action in paroxysmal dyskinesia and paroxysmal dystonic spells is not known. Gabapentin inhibits K1-evoked Ca21 increases in neocortical synaptosomes via inhibition of voltage-dependent calcium channels (VD-CCs) and reduces K1-evoked glutamate release from neocortical and hippocampal slices. [8],[9] It also inhibits excitatory neurotransmitter release in the spinal cord dorsal horn. These actions of gabapentin are hypothesized due to its selective agonist activity at neuronal GABA B receptors, which are coupled to VD-CCs. [10] Possibly, these mechanisms make gabapentin effective against other paroxysmal disorders like migraine, epilepsy, trigeminal neuralgia, neuromyotonia. These mechanisms can also be hypothesized for the response evoked in our patients of paroxysmal dystonic spells. Patients with Wilson disease may have associated clinically overt or subclinical hepatopathy. Since gabapentin has renal route of clearance, its use is safe in these patients.

In conclusion status dystonicus with paroxysmal dystonic spells is a rare but serious complication of D-penicillamine therapy in patients with Wilson disease. Underlying mechanism of this condition is not known. Gabapentin can be used to control D-penicillamine-induced paroxysmal dystonic spells in patients with Wilson disease.

 
 » References Top

1.Svetel M, Sternic N, Pejovic S, Kostic VS. Penicillamine-induced lethal status dystonicus in a patient with Wilson's disease. Mov Disord 2001;16:568-9.  Back to cited text no. 1
    
2.Glass JD, Reich SG, DeLong MR. Wilson's disease. Development of neurological disease after beginning penicillamine therapy. Arch Neurol 1990;47:595-6.  Back to cited text no. 2
    
3.Huang CC, Chu NS. Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease. Eur Neurol 1998;39:32-7.  Back to cited text no. 3
    
4.Teive HA, Munhoz RP, Souza MM, Antoniuk SA, Santos ML, Teixeira MJ, et al. Status Dystonicus: Study of five cases. Arq Neuropsiquiatr 2005;63:26-9.  Back to cited text no. 4
    
5.Linazasoro Cristóbal G. Efficacy and tolerance of gabapentin in dystonia and hemifacial spasm: A pilot study. Rev Neurol 2001;33:408-10.  Back to cited text no. 5
    
6.Kothare SV, Pollack P, Kulberg AG, Ravin PD. Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus. Pediatr Neurol 2000;22:68-71.  Back to cited text no. 6
    
7.Chudnow RS, Mimbela RA, Owen DB, Roach ES. Gabapentin for familial paroxysmal dystonic choreoathetosis. Neurology 1997;49:1441-2.  Back to cited text no. 7
    
8.Fink K, Meder W, Dooley DJ, Go¨thert M. Inhibition of neuronal Ca21 influx by gabapentin and subsequent reduction of neurotransmitter release fromrat neocortical slices. Br J Pharmacol 2000;130:900-6.  Back to cited text no. 8
    
9.Dooley DJ, Mieske CA, Borosky SA. Inhibition of K1-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-10.  Back to cited text no. 9
    
10.Bertrand S, Ng GY, Purisai MG, Wolfe SE, Severidt MW, Nouel D, et al. The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels. J Pharmacol Exp Ther 2001;298:15-24.  Back to cited text no. 10
    



This article has been cited by
1 Gabapentin can significantly improve dystonia severity and quality of life in children
Natasha Yuan-Kim Liow,Hortensia Gimeno,Daniel Edward Lumsden,Jennifer Marianczak,Margaret Kaminska,Stephen Tomlin,Jean-Pierre Sao-Ming Lin
European Journal of Paediatric Neurology. 2016; 20(1): 100
[Pubmed] | [DOI]
2 Gabapentin Can Improve Dystonia in Confirmed Wilson Disease
Margherita Lerose,Roberto Di Fabio,Mariano Serrao,Georgios Loudianos,Francesco Pierelli,Carlo Casali
The Canadian Journal of Neurological Sciences. 2014; 41(02): 284
[Pubmed] | [DOI]
3 The Pragmatic Treatment of Wilsonæs Disease
Annu Aggarwal,Mohit Bhatt
Movement Disorders Clinical Practice. 2014; 1(1): 14
[Pubmed] | [DOI]
4 Status dystonicus: a practice guide
Nicholas M Allen,Jean-Pierre Lin,Tim Lynch,Mary D King
Developmental Medicine & Child Neurology. 2013; : n/a
[Pubmed] | [DOI]
5 Advance in the pathogenesis and treatment of Wilson disease
Qin-Yun Dong,Zhi-Ying Wu
Translational Neurodegeneration. 2012; 1(1): 23
[Pubmed] | [DOI]
6 Management of status dystonicus in children. Cases report and review
Salvatore Grosso,Alberto Verrotti,Mario Messina,Michele Sacchini,Paolo Balestri
European Journal of Paediatric Neurology. 2012; 16(4): 390
[Pubmed] | [DOI]
7 Status dystonicus: Predictors of outcome and progression patterns of underlying disease
Alfonso Fasano,Lucia Ricciardi,Anna Rita Bentivoglio,Carlotta Canavese,Giovanna Zorzi,Igor Petrovic,Nikola Kresojevic,Vladimir S. Kostic,Marina Svetel,Norbert Kovacs,Istvan Balas,Agathe Roubertie,Devendra Mishra,Paolo Mariotti,Teresa Temudo,Nardo Nardocci
Movement Disorders. 2012; 27(6): 783
[Pubmed] | [DOI]
8 Metal antagonists
Meyboom, R.H.B.
Side Effects of Drugs Annual. 2012; 34: 367-375
[Pubmed]
9 Management of status dystonicus in children. Cases report and review
Grosso, S. and Verrotti, A. and Messina, M. and Sacchini, M. and Balestri, P.
European Journal of Paediatric Neurology. 2012; 16(4): 390-395
[Pubmed]
10 Status dystonicus: Predictors of outcome and progression patterns of underlying disease
Fasano, A. and Ricciardi, L. and Bentivoglio, A.R. and Canavese, C. and Zorzi, G. and Petrovic, I. and Kresojevic, N. and Kostić, V.S. and Svetel, M. and Kovacs, N. and Balas, I. and Roubertie, A. and Mishra, D. and Mariotti, P. and Temudo, T. and Nardocci, N.
Movement Disorders. 2012; 27(6): 783-788
[Pubmed]
11 Treatment of generalized dystonia
Treatment of generalized dystonia
Current Treatment Options in Neurology. 2011; 13(3): 274-289
[Pubmed]
12 Treatment of Generalized Dystonia
Naomi Lubarr,Susan Bressman
Current Treatment Options in Neurology. 2011; 13(3): 274
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow